Quarterly report pursuant to Section 13 or 15(d)

SEGMENT REPORTING

v3.22.1
SEGMENT REPORTING
3 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block]

NOTE 11 SEGMENT REPORTING

 

In accordance with ASC 280-10, the Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company has three reportable segments: BioSig Technologies, Inc. (parent), NeuroClear Technologies, Inc. and ViralClear Pharmaceuticals, Inc.

 

Information concerning the operations of the Company’s reportable segments is as follows:

 

   

Three Months Ended

March 31, 2022

(000’s)

   

Three Months Ended

March 31, 2021

(000’s)

 

Revenues (from external customers)

               

BioSig

  $ 8     $ 118  

ViralClear

    -       -  

NeuroClear

    -       -  
    $ 8     $ 118  
                 

Operating Expenses

               

BioSig

  $ 7,749     $ 7,774  

ViralClear

    322       805  

NeuroClear

    2       -  
    $ 8,073     $ 8,579  
                 

Loss from operations

               

BioSig

  $ (7,741

)

  $ (7,754

)

ViralClear

    (322

)

    (805

)

NeuroClear

    (2

)

    -  
    $ (8,065

)

  $ (8,559

)

 

   

March 31, 2022

   

December 31, 2021

 

Total Assets

               

BioSig

  $ 11,951     $ 13,595  

ViralClear

    591       1,924  

NeuroClear

    -       -  
    $ 12,542     $ 15,519